The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hepatitis diagnostic tests market was valued at US$ 5.6 Billion in 2022.
We expect the global hepatitis diagnostic tests market to exhibit a CAGR of 5.1% during 2023-2028.
The rising prevalence of hepatitis, along with the growing demand for hepatitis diagnostic tests for early detection of hepatitis A, B, or C infections, is primarily driving the global hepatitis diagnostic tests market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective hepatitis treatments to reduce the risk of the coronavirus infection upon hospital visits or interaction with medical equipment, thereby negatively impacting the global market for hepatitis diagnostic tests.
Based on the test type, the global hepatitis diagnostic tests market can be bifurcated into blood tests, imaging test, and liver biopsy. Currently, blood tests exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global hepatitis diagnostic tests market include Siemens AG, Abbott Laboratories, MedMira Inc, Qiagen GmbH, Beckman Coulter Inc (Danaher Corporation), F. Hoffmann- La Roche AG, Diasorin S.p.A, bioMeriuex SA, Hologic Inc., and Bio-Rad Laboratories Inc.
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at